These are self-pay prices and do not take into account any discounts or prescription insurance coverage that you may have. Actual prices are calculated at the time your prescription is processed by the pharmacy.
FDA grants approval for use of RISPERDAL CONSTA as both a monotherapy and adjunctive therapy in the maintenance treatment of Bipolar I Disorder (Golin/Harris International) Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. today announced the US Food and Drug Administration has approved the Supplemental New Drug Applications for the use of RISPERDAL CONSTA (risperidone) Long-Acting Treatment as both monotherapy and adjunctive therapy to lithium or valproate in the maintenance treatment of bipolar I disorder. Bipolar I disorder affects approximately one percent of the American adult population in any given year. (Source: EurekAlert! - Social and Behavioral Science)
